Lilja M, Jounela A J, Karppanen H
Eur J Clin Pharmacol. 1982;21(5):363-7. doi: 10.1007/BF00542319.
The antihypertensive effect of labetalol (L) was compared with that of clonidine (C) in a randomized cross-over study in 17 hypertensive outpatients on bendrofluazide (B). After treatment for two weeks with B(5 mg qd), either L (100 mg tid) or C (0.1 mg tid) was given and their doses were titrated at 2-weekly visits until normotension was achieve, or intolerable side-effects occurred. The treatment with B and L or C was than continued in a cross-over fashion for two 6-week periods, with 3 week diuretic washouts and subsequent dose-titration periods between the treatment periods. At the end of B, the supine blood pressure (BP) was 156/101, and at the end of B + L and B + C it was 136/91 (p less than 0.001) and 137/91 (p less than 0.0001), respectively, pooling the data from both periods. At the end of B the standing BP was 155/115, and at the end of B + L and B + C 134/100 (p less than 0.001) and 139/106 (p less than 0.0001), respectively. The mean daily doses required were L 476 mg and C 0.335 mg. On a weight basis, labetalol had about 1/1400 of the potency of clonidine. 12 patients complained of tiredness and dry mouth on clonidine and 2 patients of unsteadiness on labetalol. Labetalol caused a psoriasiform rash on the hands in one patient and limb weakness in one patient.
在一项随机交叉研究中,将拉贝洛尔(L)与可乐定(C)对17名正在服用苄氟噻嗪(B)的高血压门诊患者的降压效果进行了比较。在用B(5毫克,每日一次)治疗两周后,给予L(100毫克,每日三次)或C(0.1毫克,每日三次),并在每两周的就诊时调整剂量,直至血压正常或出现无法耐受的副作用。然后以交叉方式继续用B和L或C治疗两个6周疗程,在治疗期之间有3周的利尿剂洗脱期和随后的剂量调整期。在B治疗结束时,仰卧位血压(BP)为156/101,在B + L和B + C治疗结束时,合并两个疗程的数据,血压分别为136/91(p<0.001)和137/91(p<0.0001)。在B治疗结束时,站立位血压为155/115,在B + L和B + C治疗结束时,分别为134/100(p<0.001)和139/106(p<0.0001)。所需的平均日剂量为L 476毫克和C 0.335毫克。按重量计算,拉贝洛尔的效力约为可乐定的1/1400。12名患者抱怨服用可乐定时感到疲倦和口干,2名患者抱怨服用拉贝洛尔时感到不稳。1名患者使用拉贝洛尔后手上出现银屑病样皮疹,1名患者出现肢体无力。